Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of advanced prostate cancer in the Asia-Pacific region: Summary of the Asia-Pacific Advanced Prostate Cancer Consensus Conference 2023.
Chiong E, Murphy DG, Buchan N, Chen K, Chen SS, Chua MLK, Hamid AR, Kanesvaran R, Khochikar M, Letran J, Lojanapiwat B, Mallik I, Ng CF, Ong TA, Poon DMC, Pu YS, Saad M, Schubach K, Takahara K, Tey J, Thang SP, Toh PC, Türkeri L, Vinh NT, Williams S, Ye D; ANZUP Cancer Trials Group; Davis ID. Chiong E, et al. Among authors: takahara k. Asia Pac J Clin Oncol. 2024 Aug;20(4):481-490. doi: 10.1111/ajco.14064. Epub 2024 Apr 16. Asia Pac J Clin Oncol. 2024. PMID: 38628049
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor.
Yamamoto Y, Fujimoto S, Hashimoto M, Minami T, Fukuokaya W, Yanagisawa T, Saruta M, Takahara K, Nishimura K, Tsujino T, Nakamori Y, Hashimoto T, Kimura T, Shiroki R, Azuma H, Ohno Y, Fujita K. Yamamoto Y, et al. Among authors: takahara k. Int J Clin Oncol. 2024 Dec;29(12):1946-1958. doi: 10.1007/s10147-024-02637-6. Epub 2024 Oct 1. Int J Clin Oncol. 2024. PMID: 39352622
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium.
Uchimoto T, Iwatsuki K, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Fujimoto S, Minami T, Yamamoto Y, Yamazaki S, Takai T, Sakamoto M, Nakajima Y, Nishimura K, Maenosono R, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yoshikawa Y, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Fujita K, Kimura T, Ohno Y, Shiroki R, Azuma H. Uchimoto T, et al. Among authors: takahara k. Int J Clin Oncol. 2025 Jan;30(1):123-133. doi: 10.1007/s10147-024-02649-2. Epub 2024 Oct 28. Int J Clin Oncol. 2025. PMID: 39467994
Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.
Naiki T, Takahara K, Ito T, Nakane K, Sugiyama Y, Koie T, Shiroki R, Miyake H, Yasui T. Naiki T, et al. Among authors: takahara k. Int J Clin Oncol. 2022 Mar;27(3):592-601. doi: 10.1007/s10147-021-02071-y. Epub 2021 Nov 15. Int J Clin Oncol. 2022. PMID: 34779958
375 results